Prosecution Insights
Last updated: November 04, 2026
Application No. 17/931,000

BACTERIAL HOST STRAINS

Non-Final OA §102§103§112
Filed
Sep 09, 2022
Priority
Mar 11, 2020 — provisional 62/988,223 +2 more
Examiner
HUTSON, RICHARD G
Art Unit
1652
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aldevron L L C
OA Round
4 (Non-Final)
65%
Grant Probability
Favorable
4-5
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
592 granted / 910 resolved
+5.1% vs TC avg
Strong +53% interview lift
Without
With
+53.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
62 currently pending
Career history
964
Total Applications
across all art units

Statute-Specific Performance

§101
3.3%
-36.7% vs TC avg
§103
22.2%
-17.8% vs TC avg
§102
23.3%
-16.7% vs TC avg
§112
39.5%
-0.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 910 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants amendment incorporating the limitations of previous claim 22 into claim 20 are acknowledged. Upon further consideration it has been determined that previous claim 22 should have been included in the previous rejection based upon obviousness. For this reason the current rejection has been made non-final. Any inconvenience to applicant is regretted. Applicant's cancellation of claim 22, 68, 73, 77, 91 and 94, amendment of claims 1 and 24, in the paper of 8/12/2026, is acknowledged. Applicants' arguments filed on 8/12/2026, have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. Claims 1, 20, 24, 46, 52, 56, 66 and 68 are still at issue and are present for examination. Election/Restrictions Applicant's election without traverse of the invention of Group 1, claims 1, 16, 19-24, 39, 42, 46, 52, 56, 66, 68, 101-104), to an engineered E. coli strain host cell, in the paper of 8/18/2025, is acknowledged. Applicant's election without traverse of the invention of following species: Species Group 1: SbcC, Species Group 2: SEQ ID NO: 39 and Species Group 4: inverted repeat sequence, in the paper of 8/18/2025, is acknowledged. Claims 73, 77, 91, 94 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. Claim Objections Claims 66 and 68 are objected to because of the following informalities: Claims 66 depends from rejected claim 56. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. The rejection of claim 1 (claims 16, 19-24, 39, 42, 46, 52, 56, 66, 68, 101-105 dependent on) as being indefinite in the recitation “engineered viability- or yield-reducing mutations in any of the sbcB, recB, recD, and recJ genes” is withdrawn based upon applicants arguments presented in the paper of 12/15/2025. Claim 24 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 24 is indefinite in the recitation “cIT857 gene chromosomally integrated” in that it is unclear and confusing as what “cIT857 gene” is. In the interest of advancing prosecution “cIT857” is interpreted as “cITs857, as this is the closest thing to such in applicants specification. Appropriate correction and/or comment is required. Claim Rejections - 35 USC § 112 The rejection of claim(s) 16 and 22 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention, is withdrawn based upon applicants amendment of the claims in the paper of 12/15/2025. Claim Rejections - 35 USC § 102 The rejection of claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Darmon et al. (J. of Bacteriology, Vol 189, No. 18, pp 6686-6694, Sept. 2007) is withdrawn based upon applicants amendment of the claims in the paper of 12/15/2025. It is noted that while applicants did not specifically traverse the rejection, the strain taught by Darmon et al. is not isogenic to the strain from which it is derived, the strain from which it is derived being selected from D5Ha, DH1, JM107, JM108, JM109, MG1644, and XL1Blue (see also above rejection under 35 U.S.C. 112(b)). The rejection of claim(s) 1, 16, 19, 20, 24, 39, 42, 46, 52, 56, 101-03, is/are under 35 U.S.C. 102(a)(1) as being anticipated by Williams (US 2015/0191735) is withdrawn based upon applicants amendment of the claims and arguments presented in the paper of 12/15/2025. Specifically the GT115 strain taught by Williams comprises a Delta (mrr-hsdRMS-mcrBC). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 20, 46, 52, 56 is/are rejected under 35 U.S.C. 103 as being unpatentable over Williams (US 2015/0191735) and Darmon et al. (J. of Bacteriology, Vol 189, No. 18, pp 6686-6694, Sept. 2007). This rejection is essentially the same rejection made over previous claims 1, 20, 46, 52, 56. In response it is acknowledged that applicants amended previous claim 1 to include the limitations of previous claims 22 “wherein the temperature-sensitive lambda repressor comprises SEQ ID NO:37. As discussed below, Williams discloses the use of the temperature-sensitive lambda repressor cITs857, which though not necessarily taught by Williams inherently comprises the amino acid sequence of instant SEQ ID NO:37. Williams (US 2015/0191735) teaches methods of improving yield of plasmid vectors having a replication origin such as R6K by introducing the nucleotide sequence encoding the Rep protein into the genome of GT115, the E. coli strain in which the SbcC, SbcD and dcm genes were knocked out further using the E. coli strain containing a temperature sensitive lambda repressor for temperature expression of the Rep protein (see Examples and supporting text)(claims). Williams is silent with regard to the sbcB, recB, recD and recJ genes, which by virtue that they exist in the wild-type E. coli strains are considered to have no engineered viability- or yield-reducing mutations. Williams is silent with regard to the uvrC gene, which by virtue that they exist in the wild-type E. coli strains are considered to have no engineered viability- or yield-reducing mutations (claims 1, 16, 19, 20, 24, 39). Williams (US 2015/0191735) teaches methods of improving yield of plasmid vectors having a replication origin such as R6K by introducing the nucleotide sequence encoding the Rep protein into the genome of GT115, a E. coli strain in which the SbcC, SbcD and dcm genes were knocked out further using the E. coli strain containing a temperature sensitive lambda repressor (cITs857) for temperature expression of the Rep protein (see Examples and supporting text) (claims). Williams discloses the use of the temperature-sensitive lambda repressor cITs857, which though Williams is silent regarding its amino acid sequence, inherently comprises the amino acid sequence of instant SEQ ID NO:37. The amino acid sequence of the cITs857 temperature-sensitive lambda repressor is the same as the instant temperature-sensitive lambda repressor cITs857 of SEQ ID NO:37, based upon identical description of each temperature-sensitive lambda repressor in Williams and the instant application (i.e, cI Lambda repressor cIT857: “Lambda repressor further incorporating a C to T (Ala to Thr) mutation that confers temperature sensitivity. cITs857 is a functional repressor at 28-30.degree. C., but is mostly inactive at 37-42.degree. Also called cI857”. Williams is silent with regard to the sbcB, recB, recD and recJ genes, which by virtue that they exist in the wild-type E. coli strains are considered to have no engineered viability- or yield-reducing mutations. Williams is silent with regard to the uvrC gene, which by virtue that they exist in the wild-type E. coli strains are considered to have no engineered viability- or yield-reducing mutations (claims 1, 16, 19, 20, 24, 39). Williams further teach that the pINT pR pL R6K Rep plasmids can be integrated into alternative E. coli strains to create production hosts. Williams teach that any strain that is acceptable for plasmid production, such as JM108, BL21, DH5, DH1, DH5.alpha., GT115, GT116, DH10B, EC100, can be converted to a high yield temperature inducible R6K plasmid production host by integration of a pINT pR pL R6K Rep plasmid into the genome. The pR pL R6K Rep expression cassette may alternatively be removed from the pINT vector backbone and directly integrated into the chromosome. Williams teach the above engineered E. coli strains comprising a genomic nucleic acid sequence encoding a Rep protein having 100% sequence identity to instant SEQ ID NO:34 (see SEQ ID NO:15 of Williams). Williams teach and evidence the above engineered E. coli strains comprising a genomic nucleic acid sequence encoding a sbcB gene comprising instant SEQ ID NO:11, a recB gene comprising instant SEQ ID NO:12, a recD gene comprising instant SEQ ID NO:13 and a recJ gene comprising instant SEQ ID NO:65 as each of these genes are found in the wild-type E. coli (claim 42). Williams teach the above engineered E. coli strains comprising a plasmid vector comprising a nucleic acid having a direct repeat (claim 46) (see claim 23 and supporting text paragraph [0080]) or a mRNA vector (claim 28 and supporting text). Williams teach the above engineered E. coli strains comprising a knockout of the dcm gene (claim 103) (see Example 1 and supporting text). Darmon teaches an engineered Escherichia coli (E. coli) host cell, wherein the engineered E. coli host cell comprises a gene knockout of at least one gene selected from the group consisting of SbcC and SbcD, and wherein the engineered E. coli host cell does not include an engineered viability or yield-reducing mutation in any of sbcB, recB, recD, and recJ (p. 6686, col 2, para 7 "The E. coli MG1655 [delta)(Plac-lacZY) [delta]sbcDC PsbcDC-lacZ-aph reporter strain (DL 1649; Fig. 1A) was constructed by replacement of the sbcDC operon with a DNA fragment containing the lacZ gene and the kanamycin resistance gene aph"; p. 6687, col 2, para 1 top. 6688, col 1, para 1 "Correct excision of the sbcDC operon"; p. 6688, col 1, Fig. 1 "the cassette containing the lacZ and the kanamycin resistance genes was placed under the control of the sbcDC promoter region and fused to the beginning of the sbcD gene. sbcD', 3' truncated sbcD gene; Kanr, kanamycin resistance gene"; note, there is no mention in the full publication of any modifications to any other sbc or rec genes). One of skill in the art before the effective filing date would have been motivated to practice methods of improving yield of plasmid vectors having a replication origin such as R6K by introducing the nucleotide sequence encoding the Rep protein into the genome of GT115, a E. coli strain in which the SbcC, SbcD and dcm genes were knocked out further using the E. coli strain containing a temperature sensitive lambda repressor for temperature expression of the Rep protein as taught by Williams (US 2015/0191735) substituting the MG1655 strain taught by Darmon for the GT115 strain used by Williams. The motivation for such comes from Williams who teach that any strain that is acceptable for plasmid production, such as JM108, BL21, DH5, DH1, DH5.alpha., GT115, GT116, DH10B, EC100, can be converted to a high yield temperature inducible R6K plasmid production host by integration of a pINT pR pL R6K Rep plasmid into the genome. Further motivation comes from the fact that both strain used by Wiliams, GT115 and the MG1655 strain taught by Darmon both comprise a knockout of the sbcDC operon. The expectation of success is high as the level of expertise in bacterial genetic engineering is high and all the tools, constructs and methods needed are taught by both Williams et al. and Darmon. Claim(s) 1, 20, 46, 52, 56 is/are rejected under 35 U.S.C. 103 as being unpatentable over Williams (US 2015/0191735) and Darmon et al. (J. of Bacteriology, Vol 189, No. 18, pp 6686-6694, Sept. 2007). Remarks No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RICHARD G HUTSON whose telephone number is (571)272-0930. The examiner can normally be reached 6-3 EST Mon-Fri. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Mondesi can be reached at (408) 918-7584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. rgh 10/2/2026 /RICHARD G HUTSON/Primary Examiner, Art Unit 1652
Read full office action

Prosecution Timeline

Show 3 earlier events
Dec 15, 2025
Response Filed
Feb 17, 2026
Final Rejection mailed — §102, §103, §112
Mar 17, 2026
Response after Non-Final Action
Apr 28, 2026
Request for Continued Examination
Apr 29, 2026
Response after Non-Final Action
May 22, 2026
Non-Final Rejection mailed — §102, §103, §112
Aug 12, 2026
Response Filed
Oct 06, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781268
ROOM TEMPERATURE NUCLEIC ACID AMPLIFICATION REACTION
5y 1m to grant Granted Nov 03, 2026
Patent 12760326
RNA AND DNA BASE EDITING VIA ENGINEERED ADAR
3y 7m to grant Granted Oct 13, 2026
Patent 12747461
BACILLUS NATTO FOR PRODUCING MENAQUINONE-7 AND USE THEREOF
2y 11m to grant Granted Sep 29, 2026
Patent 12742207
FLUORESCENT CROSS-LINKED RNASE H MUTANT CONJUGATE, MIRNA COMBINATION AND APPLICATION THEREOF
3y 8m to grant Granted Sep 22, 2026
Patent 12742161
INACTIVE TELOMERASE, ADENOVIRUS ASSOCIATED VIRUS AND ARTIFICIAL MRNA HAVING SAME AND USE THEREOF
3y 6m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+53.0%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 910 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month